1. Home
  2. LIXT vs CNF Comparison

LIXT vs CNF Comparison

Compare LIXT & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

N/A

Current Price

$2.88

Market Cap

26.5M

Sector

Health Care

ML Signal

N/A

CNF

CNFinance Holdings Limited each representing twenty (20)

HOLD

Current Price

$3.27

Market Cap

27.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIXT
CNF
Founded
2005
1999
Country
United States
China
Employees
3
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
27.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
LIXT
CNF
Price
$2.88
$3.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
41.6K
2.4K
Earning Date
05-11-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$252.34
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$0.37
52 Week High
$6.09
$24.00

Technical Indicators

Market Signals
Indicator
LIXT
CNF
Relative Strength Index (RSI) 48.07 26.35
Support Level $2.50 $2.85
Resistance Level $3.30 $5.31
Average True Range (ATR) 0.24 0.26
MACD 0.03 -0.08
Stochastic Oscillator 51.56 5.98

Price Performance

Historical Comparison
LIXT
CNF

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About CNF CNFinance Holdings Limited each representing twenty (20)

CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.

Share on Social Networks: